{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:13:50Z","timestamp":1762506830324},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T00:00:00Z","timestamp":1475798400000},"content-version":"vor","delay-in-days":280,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Therapy - Oncolytics"],"published-print":{"date-parts":[[2016]]},"DOI":"10.1038\/mto.2016.16","type":"journal-article","created":{"date-parts":[[2016,6,8]],"date-time":"2016-06-08T11:45:28Z","timestamp":1465386328000},"page":"16016","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Oncolytic viruses on the cusp of success?: proceedings of the 9th International Conference on Oncolytic Virus Therapeutics"],"prefix":"10.1016","volume":"3","author":[{"given":"Cole","family":"Peters","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fares","family":"Nigim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E Antonio","family":"Chiocca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel D","family":"Rabkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1038\/mto.2016.16_bib1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/gt.2015.105","article-title":"Neuroblastomas vary widely in their sensitivities to herpes simplex virotherapy unrelated to virus receptors and susceptibility","volume":"23","author":"Wang","year":"2016","journal-title":"Gene Ther"},{"key":"10.1038\/mto.2016.16_bib2","doi-asserted-by":"crossref","first-page":"11786","DOI":"10.1128\/JVI.01356-15","article-title":"Retargeting Oncolytic Vesicular Stomatitis Virus to Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia","volume":"89","author":"Betancourt","year":"2015","journal-title":"J Virol"},{"key":"10.1038\/mto.2016.16_bib3","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/mt.2015.233","article-title":"Actin-resistant DNAse I Expression From Oncolytic Adenovirus Enadenotucirev Enhances Its Intratumoral Spread and Reduces Tumor Growth","volume":"24","author":"Tedcastle","year":"2016","journal-title":"Mol Ther"},{"key":"10.1038\/mto.2016.16_bib4","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1089\/hum.2015.098","article-title":"Systemic Delivery of an Oncolytic Adenovirus Expressing Decorin for the Treatment of Breast Cancer Bone Metastases","volume":"26","author":"Yang","year":"2015","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mto.2016.16_bib5","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nbt.2806","article-title":"Smac mimetics and innate immune stimuli synergize to promote tumor death","volume":"32","author":"Beug","year":"2014","journal-title":"Nat Biotechnol"},{"key":"10.1038\/mto.2016.16_bib6","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/cgt.2015.43","article-title":"HSV-1 as a novel therapy for breast cancer meningeal metastases","volume":"22","author":"Kuruppu","year":"2015","journal-title":"Cancer Gene Ther"},{"key":"10.1038\/mto.2016.16_bib7","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/mt.2015.219","article-title":"Perfusion Pressure Is a Critical Determinant of the Intratumoral Extravasation of Oncolytic Viruses","volume":"24","author":"Miller","year":"2016","journal-title":"Mol Ther"},{"key":"10.1038\/mto.2016.16_bib8","doi-asserted-by":"crossref","first-page":"8009","DOI":"10.1038\/ncomms9009","article-title":"Directing cell therapy to anatomic target sites in vivo with magnetic resonance targeting","volume":"6","author":"Muthana","year":"2015","journal-title":"Nat Commun"},{"key":"10.1038\/mto.2016.16_bib9","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ccell.2015.06.009","article-title":"VEGF-Mediated Induction of PRD1-BF1\/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection","volume":"28","author":"Arulanandam","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1038\/mto.2016.16_bib10","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1182\/blood-2014-07-587329","article-title":"Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells","volume":"125","author":"Villa","year":"2015","journal-title":"Blood"},{"key":"10.1038\/mto.2016.16_bib11","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/neuonc\/nov173","article-title":"Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling","volume":"18","author":"Cockle","year":"2016","journal-title":"Neuro Oncol"},{"key":"10.1038\/mto.2016.16_bib12","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/mt.2015.156","article-title":"Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses","volume":"24","author":"Rajani","year":"2016","journal-title":"Mol Ther"},{"key":"10.1038\/mto.2016.16_bib13","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/mt.2014.21","article-title":"Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults","volume":"22","author":"Kicielinski","year":"2014","journal-title":"Mol Ther"},{"key":"10.1038\/mto.2016.16_bib14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1158\/0008-5472.CAN-14-2533","article-title":"Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer","volume":"75","author":"Galanis","year":"2015","journal-title":"Cancer Res"}],"container-title":["Molecular Therapy - Oncolytics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S2372770516300407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S2372770516300407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T11:58:13Z","timestamp":1498305493000},"score":1,"resource":{"primary":{"URL":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2372770516300407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":14,"alternative-id":["S2372770516300407"],"URL":"https:\/\/doi.org\/10.1038\/mto.2016.16","relation":{},"ISSN":["2372-7705"],"issn-type":[{"value":"2372-7705","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]},"article-number":"16016"}}